New antibody weapon targets tough lymphoma

NCT ID NCT05192486

Ongoing Disease control Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study tests a new drug called GNC-038 in 12 people with diffuse large B-cell lymphoma that has come back or not responded to treatment. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. Participants receive the drug intravenously and are closely monitored for side effects and response.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B-CELL LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diffuse large B-cell lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DIFFUSE LARGE B-CELL LYMPHOMA

Contacts and locations

Locations

Affiliated Hospital of Hebei University

Baoding, Hebei, China
Ruijin Hospital, Shanghai JiaoTong University School of Medicine

Shanghai, Shanghai Municipality, 200025, China
Shenzhen Second People's Hospital

Shenzhen, Guangdong, China
The First Affiliated Hospital of Henan University of Science and Technology

Luoyang, Henan, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.